Search results
Abiomed (ABMD) Q2 Earnings Top Estimates, Margins Down
Zacks via Yahoo Finance· 2 years agoAbiomed, Inc. ABMD delivered adjusted earnings per share (EPS) of $1.30 in the second quarter of...
Abiomed (ABMD) Earnings Expected to Grow: Should You Buy?
Zacks via Yahoo Finance· 2 years agoAbiomed (ABMD) possesses the right combination of the two key ingredients for a likely earnings beat...
Abiomed's (ABMD) Impella-Related Research Gets FDA Clearance
Zacks via Yahoo Finance· 2 years agoAbiomed's (ABMD) latest regulatory clearances for clinical research of Impella heart pumps in AMI...
Why Abiomed Stock Skyrocketed Today
Motley Fool· 2 years agoShares of Abiomed (NASDAQ: ABMD) soared 50% on Tuesday after the medical device maker struck an acquisition deal with Johnson & Johnson (NYSE: JNJ). J&J...
Abiomed (ABMD) Q1 Earnings Top Estimates
Zacks via Yahoo Finance· 2 years agoAbiomed (ABMD) delivered earnings and revenue surprises of 15.74% and 0.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to...
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
Zacks via Yahoo Finance· 2 years agoAbiomed, Inc. ABMD is well poised for growth in the coming quarters, backed by strength in its...
Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoAbiomed, Inc. ABMD is scheduled to report second-quarter fiscal 2023 results on Nov 1, before market...
J&J to buy heart pump maker Abiomed for $16.6 billion ahead of consumer health spinoff
Reuters via Yahoo Finance· 2 years ago(Reuters) -Johnson & Johnson said on Tuesday it struck a deal to buy heart pump maker Abiomed Inc...
Abiomed Shares Pop 50% on Johnson & Johnson Buyout
GuruFocus.com via Yahoo Finance· 2 years agoMarking its biggest deal in nearly six years, Johnson & Johnson (NYSE:JNJ) announced on Tuesday it is buying Abiomed Inc. (NASDAQ:ABMD) for $16.6 billion...
Should Weakness in Abiomed, Inc.'s (NASDAQ:ABMD) Stock Be Seen As A Sign That Market Will Correct...
Simply Wall St. via Yahoo Finance· 2 years agoIt is hard to get excited after looking at Abiomed's (NASDAQ:ABMD) recent performance, when its...
